Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07826390 |
Synonyms | |
Therapy Description |
Limited information is currently available on PF-07826390, a putative bispecific antibody targeting LILRB1 and LILRB2 (Sep 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07826390 | PF 07826390|PF07826390 | LILRB2 Antibody 11 | Limited information is currently available on PF-07826390, a putative bispecific antibody targeting LILRB1 and LILRB2 (Sep 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06546553 | Phase I | PF-07826390 PF-06801591 + PF-07826390 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. | Recruiting | USA | 0 |